Covalon's New ColActive® Transfer-Wound Contact Layer at MEDICA -- MEDICA - World Forum for Medicine


Covalon Technologies Ltd

Covalon's New ColActive® Transfer-Wound Contact Layer at MEDICA

-Designed for the Advanced Wound and Surgical markets, Covalon has once again re-defined a category with its ColActive® Transfer – Wound Contact Layer.

-Designed to be compatible with NPWT.

-U.S. FDA cleared and available for immediate sale.

MISSISSAUGA, Ontario, Nov. 6, 2013 – Covalon Technologies Ltd. (TSXV: COV), an advanced medical technologies company, returns to MEDICA this year showcasing the first patented biological-based matrix for the growing wound contact layer market, ColActive® Transfer – Wound Contact Layer.

"We are very excited about what this product brings to advanced wound care,” says John Hands, Director of Global Marketing. “Through its patented ColActive matrix technology, ColActive Transfer is the only wound contact layer that not only protects tissue from synthetic foams and sponges, but also rapidly advances healing responses in the wound bed.”

ColActive Transfer is indicated for the management of full and partial thickness wounds including diabetic ulcers, pressure ulcers, and dehisced surgical wounds. ColActive Transfer is non-adherent and bio-resorbable; so it minimizes in-growth and eliminates the risk of painful dressing changes. It facilitates fluid transfer and it will not fragment under negative pressure, and unlike other wound contact layers, ColActive Transfer advances the healing response by attracting wound stalling proteases through its patented ColActive matrix technology.

Having recently received U.S. Food and Drug Administration (FDA) clearance for ColActive Transfer, Covalon expands on its ground-breaking portfolio of patented medical products that include:

• IV Clear™ and SurgiClear™, the world’s only dual antimicrobial silicone adhesive film dressings

• ColActive Plus – Wound Balancing Matrix, the market’s only advanced wound dressing which targets elevated protease activity and contains both CMC and alginate for optimal wound moisture balance

• SilverCoat™ Antimicrobial Foley Catheter, with CovaCoat® technology.

Covalon will showcase all of these advanced wound care and infection control technologies at MEDICA 2013, the world’s largest annual medical trade fair, from November 20 to 23 in Düsseldorf, Germany.

“Our focus is to provide technology that addresses the needs of our customers, whether they be a large OEM or a private wound clinic. I encourage those who have business relating to wound care or infection control to visit us at MEDICA,” says marketing director Hands.

To learn more about Covalon’s products and services, please come see us during MEDICA at the Ontario/Canada Pavilion, Hall 16, Booth G42 and visit the Covalon website beforehand. You may also look us up under “Companies & Products" on the portal

About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in speciality areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at Follow on Twitter @covalon.

Brian Pedlar

CEO, Covalon Technologies Ltd.


T: (905) 568-8400 x 233

F: (905) 568-5200

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.